Scarica l'app Stockscreener
1.92
0.52%
0.01
Dopo l'orario di chiusura:
1.93
0.01
+0.52%
Precedente Chiudi:
$1.91
Aprire:
$1.89
Volume 24 ore:
3.59M
Relative Volume:
1.10
Capitalizzazione di mercato:
$415.64M
Reddito:
$194.75M
Utile/perdita netta:
$-51.26M
Rapporto P/E:
-6.8571
EPS:
-0.28
Flusso di cassa netto:
$-23.38M
1 W Prestazione:
-5.88%
1M Prestazione:
+3.78%
6M Prestazione:
+45.45%
1 anno Prestazione:
+4.92%
Intervallo 1D:
$1.83
$1.94
Intervallo di 1 settimana:
$1.83
$2.03
Portata 52W:
$0.80
$2.89
Akebia Therapeutics Inc Stock (AKBA) Company Profile
Nome
Akebia Therapeutics Inc
Settore
Telefono
617-871-2098
Indirizzo
245 FIRST STREET, CAMBRIDGE, MA
Confronta AKBA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AKBA
Akebia Therapeutics Inc
|
1.92 | 415.64M | 194.75M | -51.26M | -23.38M | -0.28 |
|
ZTS
Zoetis Inc
|
164.65 | 73.07B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.87 | 47.43B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.29 | 45.72B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.37 | 17.71B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
308.27 | 14.37B | 2.76B | 1.11B | 898.10M | 22.77 |
Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-11-29 | Ripresa | BTIG Research | Buy |
| 2023-08-28 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2023-05-31 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-03-31 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2022-03-31 | Downgrade | Mizuho | Buy → Neutral |
| 2022-03-31 | Downgrade | Needham | Buy → Hold |
| 2022-03-31 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-03-08 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-01-29 | Downgrade | JP Morgan | Neutral → Underweight |
| 2019-11-14 | Reiterato | Needham | Buy |
| 2019-08-06 | Reiterato | H.C. Wainwright | Buy |
| 2019-07-11 | Reiterato | H.C. Wainwright | Buy |
| 2019-05-02 | Iniziato | JP Morgan | Overweight |
| 2019-03-20 | Iniziato | Citigroup | Neutral |
| 2018-09-07 | Ripresa | Morgan Stanley | Equal-Weight |
| 2018-08-10 | Reiterato | Needham | Buy |
| 2018-06-06 | Reiterato | H.C. Wainwright | Buy |
| 2017-12-19 | Iniziato | Piper Jaffray | Overweight |
| 2017-12-07 | Iniziato | BTIG Research | Buy |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2017-07-10 | Reiterato | H.C. Wainwright | Buy |
| 2017-04-27 | Reiterato | H.C. Wainwright | Buy |
| 2017-04-27 | Reiterato | Needham | Buy |
| 2016-12-27 | Reiterato | H.C. Wainwright | Buy |
| 2016-12-20 | Reiterato | JMP Securities | Mkt Outperform |
| 2016-11-15 | Iniziato | Aegis Capital | Buy |
| 2016-09-29 | Iniziato | Brean Capital | Buy |
| 2016-03-16 | Reiterato | Needham | Buy |
| 2016-01-21 | Iniziato | Credit Suisse | Neutral |
Mostra tutto
Akebia Therapeutics Inc Borsa (AKBA) Ultime notizie
Analysts Love These 2 Growth Stocks That Have Over 200% Upside Potential - MSN
Piper Sandler maintains Akebia stock with $6 price target By Investing.com - Investing.com Canada
Akebia Therapeutics to Present Research at National Kidney Foundation Spring Clinical Meetings 2025 - Nasdaq
Akebia Therapeutics Announces Poster Presentations at NKF Spring Clinical Meetings 2025 - GlobeNewswire
Breakthrough Kidney Disease Treatment Data: Akebia's Vadadustat Shows Promising Results - Stock Titan
Akebia Therapeutics’ $50 Million Common Stock Offering - Global Legal Chronicle
Akebia Stock Drops 28% on Pricing of $50M Common Stock Offering - MSN
Akebia Stock Drops 28% On Pricing Of $50M Common Stock Offering - Barchart
Akebia's Valuation Looks Stretched Despite Auryxia’s Loss Of Exclusivity (NASDAQ:AKBA) - Seeking Alpha
Why Akebia Therapeutics Inc. (AKBA) Went Down On Thursday? - MSN
Akebia Therapeutics Announces $50 Mln Public Offering Of Common Stock - Nasdaq
Akebia Therapeutics Announces Public Offering Pricing - TipRanks
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Crude Oil Gains Over 1%; US Weekly Jobless Claims Increase - Benzinga
JOYY, Akebia Therapeutics, Microchip Technology And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Price Is Right But Growth Is Lacking After Shares Rocket 33% - Simply Wall St
Akebia Therapeutics tumbles on deep-discounted $50 mln stock sale - TradingView
Why Five Below Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket - Benzinga
Akebia Therapeutics Prices $50 Million Public Offering -March 20, 2025 at 04:19 am EDT - Marketscreener.com
Thursday’s 10 Worst-Performing Stocks - Insider Monkey
Akebia Therapeutics Announces Pricing of Public Offering of Common Stock - GlobeNewswire
Akebia Therapeutics Announces Pricing Of Public Offering Of Common Stock -March 19, 2025 at 10:18 pm EDT - Marketscreener.com
Akebia Therapeutics Raises $50M: Major Stock Offering Priced at $2.00 Per Share - StockTitan
Akebia Therapeutics Announces Pricing of Public Offering of Common Stock - GlobeNewswire Inc.
‘Buckle Up for Another Surge,’ Says Cowen About Nvidia Stock - The Globe and Mail
Akebia Therapeutics launches public stock offering By Investing.com - Investing.com South Africa
2 No-Brainer Biotech Stocks to Buy Right Now - The Globe and Mail
SEC Form 424B5 filed by Akebia Therapeutics Inc. - Quantisnow
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Akebia Therapeutics announces proposed public offering of common stock -March 19, 2025 at 04:57 pm EDT - Marketscreener.com
Akebia Therapeutics launches public stock offering - Investing.com
Is Akebia Therapeutics (AKBA) the Best Stock to Invest in for a Stock Market Game? - Insider Monkey
Akebia Therapeutics dives on stock offering plans - TradingView
Akebia Therapeutics Announces Proposed Public Offering of Common Stock - GlobeNewswire
Akebia Therapeutics Unveils Major Public Offering: Key Details for Investors - StockTitan
Why United Airlines (UAL) Stock Is Trading Up Today - The Globe and Mail
AKBA stock touches 52-week high at $2.48 amid robust gains - Investing.com Australia
2 Large-Cap Stocks with Exciting Potential and 1 to Avoid - The Globe and Mail
Hallador Energy, Tesla And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Akebia slumps after Q4 earnings miss - MSN
H.C. Wainwright maintains Akebia stock Buy rating, $7.50 target By Investing.com - Investing.com Canada
Earnings Update: Here's Why Analysts Just Lifted Their Akebia Therapeutics, Inc. (NASDAQ:AKBA) Price Target To US$7.83 - Simply Wall St
US$7.83That's What Analysts Think Akebia Therapeutics, Inc. (NASDAQ:AKBA) Is Worth After These Results - Yahoo Finance UK
Piper Sandler raises Akebia stock target to $6 on Vafseo launch - Investing.com Canada
Akebia Therapeutics Inc (AKBA): Navigating Revenue Declines and Unlocking Growth Potential - RagingBull
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q4 2024 Earnings Call Transcript - Insider Monkey
Akebia Therapeutics Inc (AKBA) Q4 2024 Earnings Call Highlights: Navigating Revenue Declines ... - Yahoo Finance
Akebia Therapeutics Inc (AKBA) Q4 2024 Earnings Call Highlights: - GuruFocus
Akebia Therapeutics Reports Progress in Vafseo Launch - TipRanks
EnGold Announces Director Resignation - The Globe and Mail
Akebia Therapeutics: Q4 Earnings Snapshot - mySA
Akebia Therapeutics Inc Azioni (AKBA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.57%
1.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):